Limits...
Vaccine Adjuvants: from 1920 to 2015 and Beyond.

Pasquale AD, Preiss S, Silva FT, Garçon N - Vaccines (Basel) (2015)

Bottom Line: While early adjuvants (aluminum, oil-in-water emulsions) were used empirically, rapidly increasing knowledge on how the immune system interacts with pathogens means that there is increased understanding of the role of adjuvants and how the formulation of modern vaccines can be better tailored towards the desired clinical benefit.Continuing safety evaluation of licensed vaccines containing adjuvants/adjuvant systems suggests that their individual benefit-risk profile remains favorable.Adjuvants contribute to the initiation of the innate immune response induced by antigens; exemplified by inflammatory responses at the injection site, with mostly localized and short-lived effects.

View Article: PubMed Central - PubMed

Affiliation: GSK Vaccines, Avenue Fleming, 1300 Wavre, Belgium. alberta.di-pasquale@gsk.com.

ABSTRACT
The concept of stimulating the body's immune response is the basis underlying vaccination. Vaccines act by initiating the innate immune response and activating antigen presenting cells (APCs), thereby inducing a protective adaptive immune response to a pathogen antigen. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years. While early adjuvants (aluminum, oil-in-water emulsions) were used empirically, rapidly increasing knowledge on how the immune system interacts with pathogens means that there is increased understanding of the role of adjuvants and how the formulation of modern vaccines can be better tailored towards the desired clinical benefit. Continuing safety evaluation of licensed vaccines containing adjuvants/adjuvant systems suggests that their individual benefit-risk profile remains favorable. Adjuvants contribute to the initiation of the innate immune response induced by antigens; exemplified by inflammatory responses at the injection site, with mostly localized and short-lived effects. Activated effectors (such as APCs) then move to draining lymph nodes where they direct the type, magnitude and quality of the adaptive immune response. Thus, the right match of antigens and adjuvants can potentiate downstream adaptive immune responses, enabling the development of new efficacious vaccines. Many infectious diseases of worldwide significance are not currently preventable by vaccination. Adjuvants are the most advanced new technology in the search for new vaccines against challenging pathogens and for vulnerable populations that respond poorly to traditional vaccines.

No MeSH data available.


Related in: MedlinePlus

Characterization of safety from the laboratory to licensure and beyond
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4494348&req=5

vaccines-03-00320-f006: Characterization of safety from the laboratory to licensure and beyond

Mentions: The evaluation of vaccine safety begins in the laboratory and continues indefinitely after licensure (Figure 6) [57,58]. Before administration to humans, vaccine candidates undergo rigorous testing in animal models designed to detect evidence of local or systemic toxicity that might indicate a potential safety issue in humans [59]. Where possible, tests to assess the effect of administering multiple doses, vaccine quality, immunogenicity and protective efficacy are all conducted in animal models prior to the first injection in humans. Pre-clinical tests for reproductive and developmental toxicology are also done if the vaccine is intended for women of childbearing age.


Vaccine Adjuvants: from 1920 to 2015 and Beyond.

Pasquale AD, Preiss S, Silva FT, Garçon N - Vaccines (Basel) (2015)

Characterization of safety from the laboratory to licensure and beyond
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4494348&req=5

vaccines-03-00320-f006: Characterization of safety from the laboratory to licensure and beyond
Mentions: The evaluation of vaccine safety begins in the laboratory and continues indefinitely after licensure (Figure 6) [57,58]. Before administration to humans, vaccine candidates undergo rigorous testing in animal models designed to detect evidence of local or systemic toxicity that might indicate a potential safety issue in humans [59]. Where possible, tests to assess the effect of administering multiple doses, vaccine quality, immunogenicity and protective efficacy are all conducted in animal models prior to the first injection in humans. Pre-clinical tests for reproductive and developmental toxicology are also done if the vaccine is intended for women of childbearing age.

Bottom Line: While early adjuvants (aluminum, oil-in-water emulsions) were used empirically, rapidly increasing knowledge on how the immune system interacts with pathogens means that there is increased understanding of the role of adjuvants and how the formulation of modern vaccines can be better tailored towards the desired clinical benefit.Continuing safety evaluation of licensed vaccines containing adjuvants/adjuvant systems suggests that their individual benefit-risk profile remains favorable.Adjuvants contribute to the initiation of the innate immune response induced by antigens; exemplified by inflammatory responses at the injection site, with mostly localized and short-lived effects.

View Article: PubMed Central - PubMed

Affiliation: GSK Vaccines, Avenue Fleming, 1300 Wavre, Belgium. alberta.di-pasquale@gsk.com.

ABSTRACT
The concept of stimulating the body's immune response is the basis underlying vaccination. Vaccines act by initiating the innate immune response and activating antigen presenting cells (APCs), thereby inducing a protective adaptive immune response to a pathogen antigen. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years. While early adjuvants (aluminum, oil-in-water emulsions) were used empirically, rapidly increasing knowledge on how the immune system interacts with pathogens means that there is increased understanding of the role of adjuvants and how the formulation of modern vaccines can be better tailored towards the desired clinical benefit. Continuing safety evaluation of licensed vaccines containing adjuvants/adjuvant systems suggests that their individual benefit-risk profile remains favorable. Adjuvants contribute to the initiation of the innate immune response induced by antigens; exemplified by inflammatory responses at the injection site, with mostly localized and short-lived effects. Activated effectors (such as APCs) then move to draining lymph nodes where they direct the type, magnitude and quality of the adaptive immune response. Thus, the right match of antigens and adjuvants can potentiate downstream adaptive immune responses, enabling the development of new efficacious vaccines. Many infectious diseases of worldwide significance are not currently preventable by vaccination. Adjuvants are the most advanced new technology in the search for new vaccines against challenging pathogens and for vulnerable populations that respond poorly to traditional vaccines.

No MeSH data available.


Related in: MedlinePlus